Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Genesis Health vs Medro

Genesis Health
Graded #159

Higher grade

vs+4.300000000000004
Medro
Graded #255

Lower grade

The verdict

Genesis Health takes it — 67.9/100 to 63.6/100.

Genesis Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Genesis Health is a telehealth platform offering compounded semaglutide and tirzepatide injections alongside brand-name Wegovy, Ozempic, and Zepbound.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGenesis Health +1
51
50
Dose & formulationEven
77
77
Clinical oversightGenesis Health +18
89
71
Labs & monitoringGenesis Health +11
63
52
FulfillmentMedro +19
73
92
Contract termsGenesis Health +14
47
33
Genesis Health · left barMedro · right bar

The numbers

MetricGenesis HealthMedro
WeighScore67.9/10063.6/100
GradeCC
Scorecard rank#159#255
Semaglutide$175/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$235/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Genesis Health

Graded #159 · C

Strengths

  • Annual plan as low as $99/mo for semaglutide or $125/mo for tirzepatide
  • Offers both compounded and brand-name GLP-1s (Wegovy, Ozempic, Zepbound) in one platform
  • Includes health coaching, active community, and free expedited shipping on every plan
  • LegitScript certified; medications sourced from audited, licensed US compounding pharmacies
  • Same-day provider visits, personalized dosing, and 24/7 care team messaging

Where it loses points

  • States served not publicly listed; telehealth coverage unconfirmed for all states
  • Monthly starting price ($175 sema / $235 tirz) is mid-market without annual commitment
  • Labs not disclosed or included in any published plan tier
  • Brand-name GLP-1 pricing not published; insurance or coupon required
  • Compounded medications are not FDA-approved
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard